Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Friday
Apr 18th
Home
Innovative Medicine Demand
Innovative Arthritis Medicine

osteoarthritis_rheumatoid_arthritis_by_ilovepiano.jpg

Demand: Innovative Arthritis Medicine

Farmavita.Net member is developing innovative concept for glogal branding and distribution of remedies and devices for therapy of arthritis. 

Company is looking to joint-venture, collaborative development or in-licensing of  non-prescrition products, on exclusive basis. 

For more details please contact Farmavita.Net. 

Innovative Medicines Offer
Technology Platform for Controlled and Site Specific Release of Active Pharmaceutical Ingredients

marigold_by_schroppyo.jpgFarmavita.Net member has developed technology which enables development of oral dosage forms with  controlled and site specific release of active pharmaceutical ingredients. Patent pending application.

Company is looking for following types of cooperation:
- Out-licensing
- Joint-venture and private equity partners
- Collaborative product development
- Consulting or contract research contracts

 
Generic Medicine Demand
EU-CTD dossier for Nitrofurantoin

We are looking for EU-CTD dossier of Nitrofurantoin (capsules) for Lithuanian market.

If you have some offers, please, contact me by my email egleb@aconitum.lt

 

Regards,

Egle Baceviciute 

Generic Medicines - Offer
Risedronate 75mg We offer for out-licensing European e-CTD format of Risedronate 75mg and/or Risedronate 35mg f.c. tablets. Dossier is ready and is currently under registration in several EU countries. Preferred model is of business cooperation is License Fee + Supply with finished product.
 
OTC / Nutraceutical Demand
DL-Aspirin + Glycine

We would like to express our interest in acquiring CTD Europeen format for DL-Aspirin+Glycine (90%/10%) oral soluble form with supply of the sam. 

Please post your offer at below comment form. 

API/Technology Demand
SPECTINOMYCIN HCL -COMMERCIAL TECHNOLOGY WANTED

WE REQUIRE PLANT PROVEN COMMERCIAL TECHNOLOGY TO MANAUFACTURE SPECTINOMYCIN HCL IN INDIA . TECHNOLOGY LICENCENSORS/MANUFACTURING COMPANIES/CONSULTANTS TO SUBMIT THEIR TECHNICAL AND COMMERCIAL PROFILE AND BUSINESS TERMS.

 

CONTACT; MR.ARVIND GANDHI -GM MKTG ( API AND FINE CHEMICALS) ASENCE PHARMA PVT.LTD.,MUMBAI.

EMAIL; saramvitc@asedvnsmc.com

 

              

 
Open Innovation
Open Source BioPharma Systems

Open source systems lure drug developers

apple2.jpgThe gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.

Life Science Article
Micro- and Nanoscale Technologies

cell.jpg

Micro- and nanoscale technologies for tissue engineering and drug discovery applications

Micro- and nanoscale technologies are emerging as powerful enabling tools for tissue engineering and drug discovery. In tissue engineering, micro- and nanotechnologies can be used to fabricate biomimetic scaffolds with increased complexity and vascularization.

The whole 16 pages article is available for download at Downloads section of Farmavita.Net.   

 
Events
Pharma CI Conference & Exhibition

Pharma CI Conference & Exhibition 

September 9-10, 2014, Parsippany, New Jersey, USA

2014_pharmaci_banner_150x150.gif

The Pharma CI Conference & Exhibition is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the rare chance to network with all the industry's luminaries. This is the biggest and best gathering of pharmaceutical competitive intelligence thought leaders (75+ speakers)!

Market Report
Renal Cell Cancer datamonitor_logo.gif

 

 

Pipeline: Renal Cell Cancer

Introduction
Seven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still required. 

 
Advertisement
 

Featured Partners

 allergies150x150_2.jpg
imf14-pharma_150x150_engl.gif
bionetworks-150x150.jpg
mdc_150_150.jpg
pharmprom_150x150_engl.gif
lyophilisation_150_x_150.jpg  
2014-pmr-canada-banner-150x150.gif 
it_india_150x150.jpg
    2014_pharmaci_banner_150x150.gif      

Login to Farmavita.Net

membership is FREE

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 86 guests online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

pc_150x150.gif

Reports

rbhc0264_privatehealthcare.gif 

Events

150x150_logo.jpg

REPORTS

farmavita_research-store.gif